Loading…
Kiora Pharmaceuticals, Inc. has granted Senju Pharmaceutical Co., Ltd. an option to develop and market the vision-restoring drug KIO-301 in Asia.
Kiora Pharmaceuticals, Inc. (XNAS: KPRX) has granted Senju Pharmaceutical Co., Ltd. an option to develop and market the vision-restoring drug KIO-301 in Asia. This agreement allows Senju Pharmaceutical to advance the development and commercialization of KIO-301 in the Asian market.
The collaboration aims to leverage Senju Pharmaceutical's expertise in ophthalmology to bring KIO-301 to patients in Asia. Kiora Pharmaceuticals retains the rights to develop and market the drug in other regions.
As of the latest available data, Kiora Pharmaceuticals has a free float of 3,558,300 shares and 3,677,900 shares outstanding.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.